BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
By Bridgepoint Medical Inc., PRNE
November 22nd, 2009
MINNEAPOLIS, November 23 - BridgePoint Medical announced today that it received European CE Mark
(Conformite Europeene) for its coronary and peripheral Chronic Total
Occlusion (CTO) Crossing System comprised of the CrossBoss(TM) CTO Crossing
Catheter and the Stingray(R) CTO Re-Entry System. The BridgePoint System is a
series of interventional catheters that are designed to navigate highly
diseased arteries in preparation for blood flow restoration via angioplasty
and stenting.
The National Heart, Lung and Blood Institute (NHLBI) estimates that
Chronic Total Occlusions (CTOs) are common and are found in approximately
one-third of patients who undergo angiography, which equates to a world wide
annual incidence of 1.3 million patients. Interventional cardiologists are
currently unable to broadly treat patients with chronic total occlusions due
to the procedurally challenging and advanced nature of the disease. For these
patients, alternatives include bypass surgery or pharmacologic therapy. For
the millions of people with living with a coronary CTO, chest pain, shortness
of breath and fatigue are part of every day life.
"We have seen many attempts to implement new tools for the treatment of
chronic coronary occlusions over the years, but until now none of them have
provided any advantage over the current treatment of using specialty
guidewires," said Gerald Werner M.D. Ph.D., Professor at the Klinikum
Darmstadt in Darmstadt, Germany. "This system is the first to provide a new
option for the frequent situation when our guidewires do not reach the vessel
beyond the occlusion. The BridgePoint system makes it possible to find the
true vessel lumen and conclude the treatment successfully."
The disposable BridgePoint Catheter System does not require the use of
expensive and cumbersome capital equipment and uses techniques that are
common in interventional medicine.
"The CrossBoss and Stingray devices provide interventionalists in the
E.U. with new opportunities to treat patients with highly diseased arteries.
We believe that these devices represent an important new advance in
interventional cardiology," said Chad Kugler, Co-Founder, President and
General Manager, BridgePoint Medical. "This technology exemplifies
BridgePoint's innovative approach to CTO treatment and our commitment to
further reduce the need for invasive bypass surgery."
The BridgePoint Medical CrossBoss and Stingray are indicated in the
European Union for adults with coronary or peripheral artery disease, age 18
and older. The devices are contraindicated for use in cerebral vasculature.
Clinical Trial Summary
In a prospective clinical trial conducted in the European Union and a
post-market registry conducted primarily in South America the BridgePoint
System was 67%-85% successful in placing an interventional guidewire beyond a
chronic total coronary occlusion. Complications with the system were similar
to general PCI and stenting.
The BridgePoint devices are currently under clinical investigation in the
U.S. and are not commercially available for treating CTO in the U.S.
About Chronic Total Coronary Occlusions
The National Heart, Lung and Blood Institute (NHLBI) estimates that
Chronic Total Occlusions (CTOs) are common and are found in approximately
one-third of patients who undergo angiography. Patients surviving with a CTO
commonly suffer from poor blood circulation to the heart muscle that induces
symptoms such as chest pain (angina), shortness of breath and fatigue.
Studies also show that the patients living with an untreated coronary CTO are
at higher risk of death.
About BridgePoint Medical
BridgePoint Medical, Inc. is a privately held company established in 2006
to design, develop and commercialize new technologies and techniques to treat
challenging coronary artery disease. Investors include New Enterprise
Associates, Polaris Venture Partners, Foundation Medical Partners and Michael
Berman.
Chad Kugler, President and General Manager of BridgePoint Medical, Inc., +1-763-225-8500
Filed under Clinical Trials / Medical Discoveries, Health, Health Care / Hospitals, Medical Equipment, Pharmaceuticals | Tags: Bridgepoint Medical Inc., France, Germany, Minneapolis, Minnesota, United Kingdom | Comment Below
Related Press Releases OpenSymmetry Opens Australian Office and Provides Consultancy to Australia's 2nd Largest BankNovember 8th, 2009 SYDNEY -
- Mark Wild Appointed to Head up Australian Office
OpenSymmetry, a worldwide leader in outsourced incentive management and reward technology solutions, today announced the opening of its new Australian offices in Sydney, New South Wales and the appointment of Mark Wild as Managing Director of OpenSymmetry Australia Pty Ltd. The new office has already secured a major client and will be providing incentive management services to Australia's 2nd largest bank. New Campaign Urges Public To Help Prevent FloodingSeptember 30th, 2009 BRADFORD, England - A new public information campaign launched today (Thursday October 1), is urging the public to stop putting unwanted items down the sewer. To view Mulitmedia New Release, please click:
www.prnewswire.com/mnr/yorkshirewater/39646/
Each year 75 per cent of all sewer blockages in England and Wales are caused because of people mistakenly disposing of items down drains or sewers and half of all flooding incidents are caused by these blockages. 10 Years of the Estrel Convention CenterSeptember 14th, 2009 BERLIN -
- In September, Europe's Biggest Convention, Entertainment and Hotel Complex Celebrates the 10th Birthday of its Convention Centre
- Cross reference: Picture is distributed via EPA (European Pressphoto Agency) and can be downloaded free of charge at: www.presseportal.de/pm/23285?keygroup=bild -
Over 12,800 functions, more than 4.5 million guests and an unparalleled variety of events: the Estrel Convention Center is celebrating its 10th birthday this year!
Even the opening of the Estrel Convention Center in September 1999 - having been under construction for only eleven months- was a sensation: with a live elephant, symbolic of the size of the new convention centre, in the middle of the 4,700 metre square convention hall. Just a day later, shortly before the official opening gala with a concert by Julio Iglesias, the first major event was held in the Convention Center, attended by 7,500 guests. vProtect Luminal Shield (TM) from Prescient Medical Receives CE MarkAugust 23rd, 2009 DOYLESTOWN, Pennsylvania -
- Novel Self-Expanding Platform for Treatment of Coronary Artery Disease Receives European Regulatory Clearance
Medical device pioneer, Prescient Medical, Inc., announced today that it has received European CE Mark (Conformite Europeene) approval to commercialize its vProtect(TM) Luminal Shield Stent System. The device is now approved for use in improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease. Germany Rediscovers Kaiser Otto IV - Lower Saxony State Exhibition Opens on 08.08.2009 in BraunschweigAugust 6th, 2009 BRAUNSCHWEIG, Germany - To mark the occasion of the 800th anniversary of the crowning of Otto IV, the only Holy Roman Emperor from the House of Welf, the Lower Saxony state exhibition entitled "Otto IV - Dream of a Welf Empire" will be held. Otto IV was the son of Henry the Lion and Matilda of England, Duchess of Saxony, and from 1209 to 1218 he reigned as the Holy Roman Emperor. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring SystemJuly 6th, 2009 AARHUS, Denmark - Unisense FertiliTech A/S ( www.fertilitech.com) announces that the EmbryoScope(TM) Embryo Monitoring System and EmbryoSlide(TM) tray have received CE approval as class IIa medical devices for use in IVF. Unisense Fertilitech A/S also received the DS/EN ISO13485:2003 and AC:2007 quality system certificate for production, installation and servicing of IVF incubators and related accessories
(Photo: www.newscom.com/cgi-bin/prnh/20090706/353010 )
Francesca Bahr, sales manager at Unisense FertiliTech A/S says "the CE mark will allow us to market the instrument to Assisted Reproduction clinics across Europe, with the goal of improving embryo assessment and to facilitate the goal of elective single embryo transfer". Heart Disease Treatment BreakthroughMay 31st, 2009 GATESHEAD, England - A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the killer disease. GP Dr Rob Hicks said the launch of Ateronon, the natural supplement developed by Cambridge scientists, was a huge breakthrough in the treatment of heart disease related illnesses that can cause heart attacks and stroke. L'Oréal Welcomes the UK High Court of Justice's Guiding Comments on Measures to Prevent Trade Mark Infringement on eBay's UK PlatformMay 21st, 2009 CLICHY, France - In a decision passed today by the UK High Court of Justice, the court agreed with the view held from the outset by L'Oréal, that eBay could do more to prevent trade mark infringement and suggested 10 measures:
- filter listings before they are posted on the Site - use additional filters, including filters to detect listings of not-for-sale products and unboxed products - filter descriptions as well as titles - require sellers to disclose their names and addresses when listing items - impose additional restrictions on the volumes of high risk products, such as fragrances and cosmetics, that can be listed at any one time - be more consistent in their policies, for example regarding sales of unboxed products - adopt policies to combat types of infringement which are not presently addressed, and in particular the sale of non-European Economic Area (EEA) goods without the consent of the trade mark owners - take greater account of negative feedback (from site users) - apply sanctions more rigorously - be more rigorous in suspending accounts linked to those of users whose accounts have been suspended
The UK High Court of Justice considered that the relevant European trade mark law and the eCommerce Directive were unclear and referred nearly all the issues to the European Court of Justice (ECJ) for further guidance. Since L'Oréal has maintained that eBay cannot benefit from the regime of liability for hosting providers under the eCommerce Directive, it is satisfied to note that the UK Court preferred its view before referring the matter to the ECJ. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging CatheterMay 18th, 2009 BURLINGTON, Massachusetts and ROTTERDAM, Netherlands - InfraReDx, Inc. announced today the first use in patients of a novel coronary catheter that uses both light and sound to image coronary plaques. New Book Shows Billions are Being Wasted on StatinsMarch 15th, 2009 LONDON - Millions of people already take a statin to lower their cholesterol and
millions more are about to be prescribed these drugs under current
guidelines. However, a new book provides substantial evidence to show that
most people do not need to lower their cholesterol.
Related News Bridgepoint 3Q profit, guidance top expectations as student enrollments jump; shares riseNovember 4th, 2009 Bridgepoint 3Q profit, guidance top expectationsSAN DIEGO — Online education provider Bridgepoint Education Inc. said Wednesday that net income in the third quarter more than doubled as the school enrolled more students in its Web classes. Bridgepoint Education, Quiksilver, Ulta Salon, Esterline are among big market moversSeptember 4th, 2009 Bridgepoint Ed, Quiksilver, Ulta Salon big moversNEW YORK — The following stocks were among those that moved substantially or traded heavily Friday on the New York Stock Exchange and Nasdaq Stock Market:
NYSE:
Bridgepoint Education Inc., down $2.66 to $15.57
The San Diego-based education company said it expects a federal audit to result in proposed fines and other action.
H&R Block Inc., down 39 cents to $16.62
The nation Merck fertility drug receives positive recommendation by European advisory committeeNovember 20th, 2009 Merck fertility drug gets European recommendationWHITEHOUSE STATION, N.J. — Drug developer Merck & Co. Why our red blood turns blue after entering veinsAugust 29th, 2009 WASHINGTON - Ever imagined why our blood, which is actually red in colour turns blue in veins? Well, it's because of the oxygen. According to experts, heart pumps blood to the lungs to pick up oxygen. Anika Therapeutics receives European approval for wrinkle treatment Elevess LightNovember 19th, 2009 Anika gets European approval on wrinkle productBEDFORD, Mass. — Skin therapy company Anika Therapeutics Inc. Trans fats impede many steps in blood flow regulationJune 17th, 2009 WASHINGTON - Trans fatty acids, present in partially hydrogenated vegetable oils in processed foods, interfere with more than one key enzyme in the regulation of blood flow, according to a study. University of Illinois emeritus veterinary biosciences professor Fred Kummerow claims that this is the first time that any study has revealed a new way in which these "trans fats" gum up the cellular machinery that keeps blood moving through arteries and veins. French education minister says protesting university students won't get diplomasMay 11th, 2009 France: No diplomas for student protestersPARIS — France's education minister says protesting students who have blocked universities for months will not get diplomas. Xavier Darcos says just a handful of students protesting against a proposed university reform have succeeded in disrupting operations at several French universities. Latvia receives euro1.2B from EU, optimistic about getting euro200M from IMFJuly 27th, 2009 Latvia receives bailout funds from EURIGA, Latvia — Recession-plagued Latvia breathed a sigh of relief Monday after receiving a large bailout loan from the European Union and approving austerity measures that will pave the way for winning funds from the International Monetary Fund. Latvia received euro1.2 billion ($1.7 billion) in bailout funds from the European Union, money the Baltic state desperately needs to balance its budget, which is under duress as the economy contracts at an unprecedented rate. Stock futures point toward higher opening as investors wait to hear from Fed chairmanAugust 21st, 2009 Stock futures point to modestly higher openingNEW YORK — Stock futures are pointing to a modestly higher opening as investors await a new report on housing and the dollar resumed its slide. Overseas, Asian markets declined Wednesday while European markets are rising. Solar eclipse blocked by clouds in TibetJuly 22nd, 2009 LHASA - Tibet's Cona county was one of the first places in China to view the solar eclipse, which occurred at 8:01 a.m Wednesday, according to an observatory under the Chinese Academy of Sciences (CAS). However, the solar view from Cona was blocked by overcast, according to sources from the CAS Purple Mountain Observatory based in Nanjing, eastern Jiangsu province.
|
|